FIELD: biotechnology.
SUBSTANCE: following is proposed: antigen-binding polypeptide that binds to a human PD-L1 epitope containing a heavy chain variable domain and a light chain variable domain, and their respective sequences essentially consist of pairs of sequences selected from a specific group, a nucleic acid molecule encoding an antigen-binding polypeptide, a pharmaceutical composition for use in inhibiting the biological activity of PD-L1, as well as a method of therapeutic treatment of a subject.
EFFECT: invention is used to the treatment of cancer containing a portion of tumor cells expressing a detectable amount of PD-L1.
12 cl, 28 dwg, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIBODY SPECIFICALLY BINDING WITH THE N-TERMINAL OF LYSYL-TRNA SYNTHETASE AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF DISEASES CAUSED BY CELL MIGRATION | 2018 |
|
RU2749591C1 |
| DOG ANTIBODIES WITH MODIFIED CH-CH SEQUENCES | 2014 |
|
RU2815059C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| ANTIBODIES TO PAC1 AND THEIR APPLICATION OPTIONS | 2019 |
|
RU2781553C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
